NCT00002400已完成不适用
An Open-Label Randomized Study of Delavirdine Mesylate (Rescriptor) in Combination With Zidovudine (Retrovir) and Two Doses of Indinavir (Crixivan) Versus Zidovudine, Lamivudine (Epivir), and Indinavir in HIV-1-Infected Individuals
Pharmacia and Upjohn2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 45
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.
详细描述
In this multicenter, open-label study, 45 HIV-1-positive patients receive either combination drug therapy with delavirdine (DLV), zidovudine (ZDV), and indinavir (IDV) or combination drug therapy with ZDV, lamivudine (3TC), and IDV. NOTE: Patients are treated for 24 weeks and may opt to continue on study for 24 additional weeks, if HIV-1 RNA is less than 5,000 copies/ml or at the investigator's discretion.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV-1 positive.
- •CD4 count above
- •HIV-1 RNA greater than 20,
- •Prior Medication:
- •Less than 1 month prior treatment with zidovudine.
排除标准
- •Prior Medication:
- •Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.
- •Prior ZDV of greater than 1 month total duration.
- •Prior Treatment:
- •Lamivudine.
- •Protease inhibitors.
- •Non-nucleoside reverse transcriptase inhibitors.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 InfectionHIV InfectionsNCT00414518University of Colorado, Denver16
已完成
不适用
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected PatientsHIV InfectionsNCT00002401Pharmacia and Upjohn160
撤回
2 期
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionHIV InfectionsNCT00006339National Institute of Allergy and Infectious Diseases (NIAID)
已完成
2 期
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected PatientsHIV InfectionsNCT00002234Gilead Sciences25
已完成
不适用
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole TreatmentCandidiasis, OralHIV InfectionsNCT00002394Novartis30